Detalles de la búsqueda
1.
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.
Clin Lung Cancer;
2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38880664
2.
Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Cancer Discov;
2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38564707
3.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Nat Cancer;
2024 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38528112
4.
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
JCO Glob Oncol;
10: e2300483, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38484195
5.
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.
JCO Precis Oncol;
8: e2300371, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330261
6.
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Future Oncol;
20(16): 1057-1067, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348690
7.
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Cancer Cell;
42(3): 429-443.e4, 2024 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38366589
8.
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab.
Oncol Ther;
12(1): 175-182, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280181
9.
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Lung Cancer;
188: 107469, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38219288
10.
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
J Clin Oncol;
42(3): 324-335, 2024 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37976444
11.
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Future Oncol;
20(6): 297-306, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916501
12.
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Lung Cancer;
186: 107418, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37931445
13.
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Lung Cancer;
186: 107423, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995456
14.
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Crit Rev Oncol Hematol;
192: 104190, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37871779
15.
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
BMC Cancer;
23(1): 1000, 2023 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37853341
16.
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer.
Front Oncol;
13: 1215524, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37700839
17.
EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists.
Oncol Ther;
11(4): 419-431, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37750968
18.
High levels of expression of Trop-2 in thymic epithelial tumors.
Lung Cancer;
184: 107324, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37573703
19.
Zipalertinib in EGFR Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting.
J Clin Oncol;
41(26): 4200-4203, 2023 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37487151
20.
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Front Oncol;
13: 1115405, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37168365